Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOLLON: Long-term safety of erenumab in migraine
NCT04084314Phase 4Completed
- Sponsor
- Novartis
- Start
- Sep 2019
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erenumab in migraine, sponsored by Novartis. Primary endpoint: Exposure Adjusted Incidence Rate of Adverse Events up to 128 weeks. Started Sep 2019; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04084314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084314.